Replies to post #55127 on Ayala Pharmaceuticals Inc (fka ADXS)

[jckrdu]

No, Advaxis is running Aim2serv. Stendhal is contributing $10M to Aim2serv.

Below is the link to Aim2serv on clinicaltrials.gov. Advaxis is the sponsor.
https://www.clinicaltrials.gov/ct2/show/NCT02853604?term=advaxis&draw=3&rank=3

Below is the 2016 PR announcing the partnership with Stendhal.
http://ir.advaxis.com/press-release/business-development/advaxis-axalimogene-filolisbac-be-developed-and-commercialized

Under the terms of the Agreement, Stendhal will pay $10 million toward the expenses of AIM2CERV, a planned global Phase 3 clinical trial in women with high-risk, locally advanced cervical cancer. This payment covers a significant portion of the total planned study costs. Stendhal will also work with Advaxis to complete the clinical trial of axalimogene filolisbac in Mexico, Brazil, Colombia, and other investigational sites in Latin American countries. Additionally, Stendhal will manage the regulatory approval process, promotion, commercialization and market access for axalimogene filolisbac in these markets. Advaxis and Stendhal will share profits on a pre-determined basis.

My question is, does anyone know if Stendhal ever initiated any trials for AXAL in any of those other countries.

[Traderbx]

"Isn’t Stendhal running the Aim2cerv?"

In Latin America only, yes.